Orelabrutinib in the First-line Treatment of HP-positive Gastric MALT Lymphoma: a Multicenter, Open-label, Randomized Controlled Trial
Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma
• Age ≥ 18 years old
• Histologically confirmed gastric mucosa-associated lymphoid tissue (MALT) lymphoma;
• Current infection with Helicobacter pylori (Hp): Diagnosis can be made if any of the following criteria are met: a) Positive result in at least one of the following: RUT (rapid urease test), histological staining, or bacterial culture of gastric mucosal tissue; b) Positive result in 13C or 14C-UBT (urea breath test); c) Positive result in HpSA detection. A positive result in serum Hp antibody test indicates past infection, and patients who have never been treated can be considered as having current infection.
• ECOG (Eastern Cooperative Oncology Group) performance status 0-2.
• Lugano staging I-II1.
• Signed informed consent form.
• Evaluable lesions present.